IQV · Iqvia Holdings Inc.
Market Cap
$44.69B
Shares
166.90M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$16.31B
+5.9%
FY2025
Net Income
$1.36B
-0.9%
FY2025
Operating Margin
13.38%
-0.9pp
FY2025
Diluted EPS
$7.84
+4.7%
FY2025
Operating Cash Flow
$2.65B
-2.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $16.63B | $16.31B | $15.41B | $14.98B | $14.41BG | $13.87BG | $11.36B | $11.09B | $10.41B | $9.74B | $6.88B | $5.74B | $5.46B | $5.1B | $4.87B | $4.33B | |
| — | — | — | — | — | — | — | — | — | — | — | $3.34M | $5.79M | $4.96M | $10.43M | $9.99M | |
| $1.99B | $2B | $1.99B | $2.05B | $2.07B | $1.96B | $1.79B | $1.73B | $1.72B | $1.62B | $1.02B | $815M | $781M | $860.51M | $817.76M | $762.3M | |
| — | $984M | $965M | $974M | $970M | $1.12B | $1.15B | $1.07B | $1.02B | $886M | $210M | $67M | $58M | $51.45M | $46.44M | $35.55M | |
| $1.17B | $1.14B | $1.11B | $1.13B | $1.13B | $1.26B | $1.29B | $1.2B | $1.14B | $1.01B | $289M | $128M | $121M | $107.5M | $98.29M | $92M | |
| $127M | $105M | $67M | $84M | $28M | $20M | $52M | $75M | $68M | $63M | $71M | $30M | $9M | $14.07M | $18.74M | $22.12M | |
| $2.2B | $2.18B | $2.2B | $1.98B | $1.8B | $1.39B | $731M | $777M | $741M | $665M | $576M | $646M | $590M | $462.33M | $396.44M | $345.25M | |
| — | 13.38% | 14.29% | 13.19% | 12.48% | 10.04% | 6.44% | 7.01% | 7.12% | 6.83% | 8.37% | 11.26% | 10.81% | 9.07% | 8.15% | 7.98% | |
| $3.37B | $3.33B | $3.32B | $3.1B | $2.93B | $2.66B | $2.02B | $1.98B | $1.88B | $1.68B | $865M | $774M | $711M | $569.84M | $494.72M | $437.26M | |
| $756M | $729M | $670M | $672M | $416M | $375M | $416M | $447M | $414M | $346M | $144M | $101M | $101M | $123.51M | -$134.37M | $109.07M | |
| $44M | $45M | $47M | $36M | $13M | $6M | $6M | $9M | $8M | $7M | $4M | $4M | $4M | $3.94M | $3.07M | $3.94M | |
| $110M | $99M | $90M | $124M | -$33M | $130M | $65M | $37M | -$5M | -$13M | $11M | -$2M | $8M | $185K | $3.57M | -$9.07M | |
| $41M | $22M | $5M | $0 | -$12M | $6M | $7M | -$9M | $15M | $10M | -$4M | $8M | $5M | -$1.12M | $2.57M | $70.76M | |
| — | — | — | — | — | — | — | — | — | — | — | $0 | $5M | $0 | $0 | — | |
| $1.6B | $1.59B | $1.67B | $1.46B | $1.36B | $1.13B | $373M | $352M | $328M | $294M | $416M | $539M | $501M | $323.12M | $267.43M | $184.68M | |
| $250M | $252M | $301M | $101M | $260M | $163M | $72M | $116M | $59M | -$992M | $325M | $159M | $149M | $95.97M | $93.36M | $15.11M | |
| $1.39B | $1.36B | $1.37B | $1.36B | $1.09B | $966M | $279M | $191M | $259M | $1.28B | $72M | $387M | $357M | $226.59M | $177.55M | $241.77M | |
| — | 8.34% | 8.91% | 9.06% | 7.57% | 6.96% | 2.46% | 1.72% | 2.49% | 13.11% | 1.05% | 6.75% | 6.54% | 4.44% | 3.65% | 5.59% | |
| — | $1M | $0 | $0 | $0 | $5M | $29M | $36M | $25M | $19M | $15M | $1M | $118K | -$564K | -$915K | $1.45M | |
| — | $1.46B | $1.2B | $1.22B | $770M | $775M | $385M | $104M | -$14M | $1.89B | -$382M | $335M | $298M | $218.52M | $162.37M | $217.67M | |
| USD/shares | $8.12 | $7.91 | $7.57 | $7.39 | $5.82 | $5.05 | $1.46 | $0.98 | $1.27 | $5.86 | $0.48 | $3.15 | $2.78 | $1.83 | $1.53 | $2.08 |
| USD/shares | $8.05 | $7.84 | $7.49 | $7.29 | $5.72G | $4.95G | $1.43 | $0.96 | $1.24 | $5.74 | $0.47 | $3.08 | $2.72 | $1.77 | $1.51 | $2.05 |
| shares | — | 171.9M | 181.3M | 183.8M | 187.6M | 191.4M | 191.3M | 195.1M | 203.7M | 217.8M | 149.1M | 123M | 128M | 124.15M | 115.71M | 116.23M |
| shares | — | 173.5M | 183.4M | 186.3M | 190.6M | 195M | 195M | 199.6M | 208.2M | 222.6M | 152M | 125.6M | 131.1M | 127.86M | 117.8M | 117.94M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2025: $12.64B in buybacks, $856.17M in dividends.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.51×
Peer median 6.07×
EV/EBIT
26.55×
Peer median 32.70×
P/E (TTM)
33.26×
Peer median 33.93×
Peer medians compare against the 19 similar-size Diagnostics & Research companies (of 46 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Research and Development Solutions | $8,896,000,000 | $8,527,000,000 | $8,395,000,000 | $7,921,000,000 | $7,556,000,000 | $5,760,000,000 | $5,788,000,000 | $5,465,000,000 |
| Technology and Analytics Solutions | $6,626,000,000 | $6,160,000,000 | $5,862,000,000 | $5,746,000,000 | $5,534,000,000 | $4,858,000,000 | $4,486,000,000 | $4,137,000,000 |
| Contract Sales and Medical Solutions | $788,000,000 | $718,000,000 | $727,000,000 | $743,000,000 | $784,000,000 | $741,000,000 | $814,000,000 | $810,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Americas | $7,745,000,000 | $7,356,000,000 | $7,552,000,000 | $7,048,000,000 | $6,848,000,000 | $5,419,000,000 | $5,462,000,000 | $4,998,000,000 |
| EMEA | $5,185,000,000 | $4,920,000,000 | $4,459,000,000 | $4,366,000,000 | $4,357,000,000 | $3,695,000,000 | $3,477,000,000 | $3,448,000,000 |
| Asia Pacific | $3,380,000,000 | $3,129,000,000 | $2,973,000,000 | $2,996,000,000 | $2,669,000,000 | $2,245,000,000 | $2,149,000,000 | $1,966,000,000 |
Key facts
CIK
1478242
CUSIP
46266C105
13F (30d)
538 filings
516 filers
Visit website
Investor relations